Subsets | Case/control | Genotype Frequencies (%) | Chi square test for trend (p value) | ||
---|---|---|---|---|---|
 |  | 1:1 | 1:2 | 2:2 |  |
IL1A +4845 G>T | |||||
Overall | Cancers (n = 697) | 360 (51.6%) | 275 (39.5%) | 62 (8.9%) | X2 = 3.71; p = 0.05 |
 | Controls (n = 498) | 215 (43.2%) | 245 (49.2%) | 38 (7.6%) |  |
Positive Family History | Cancers (n = 192) | 106 (55.2%) | 71 (37%) | 15 (7.8%) | X2 = 2.74; p = 0.10 |
 | Controls (n = 104) | 44 (42.3%) | 52 (50%) | 8 (7.7%) |  |
Negative Family History | Cancers (n = 505) | 254 (50.3%) | 204 (40.4%) | 47 (9.3%) | X2 = 1.47; p = 0.23 |
 | Controls (n = 394) | 171 (43.4%) | 193 (49%) | 30 (7.6%) |  |
Young cancers vs. controls | Cancers (n = 113) | 55 (48.7%) | 43 (38%) | 15 (13.3%) | X2 = 0; p = 0.98 |
 | Controls (n = 498) | 215 (43.2%) | 245 (49.2%) | 38 (7.6%) |  |
IL1B -511 C>T | |||||
Overall | Cancers (n = 703) | 339 (48.2%) | 294 (41.8%) | 70 (10%) | X2 = 0.10; p = 0.75 |
 | Controls (n = 489) | 232 (47.4%) | 206 (42.1%) | 51 (10.4%) |  |
Positive Family History | Cancers (n = 195) | 96 (49.2%) | 85 (43.6%) | 14 (7.2%) | X2 = 0.45; p = 0.51 |
 | Controls (n = 103) | 48 (46.6%) | 45 (43.7%) | 10 (9.7%) |  |
Negative Family History | Cancers (n = 508) | 243 (47.8%) | 209 (41.1%) | 56 (11%) | X2 = 0.003; p = 0.96 |
 | Controls (n = 386) | 184 (47.7%) | 161 (41.7%) | 41 (10.6%) |  |
Young cancers vs. controls | Cancers (n = 115) | 55 (47.8%) | 49 (42.6%) | 11 (9.6%) | X2 = 0.033; p = 0.86 |
 | Controls (n = 489) | 232 (47.4%) | 206 (42.1%) | 51 (10.4%) |  |
IL1B +3954 C>T | |||||
Overall | Cancers (n = 691) | 410 (59.3%) | 242 (35%) | 39 (5.6%) | X2 = 1.12; p = 0.29 |
 | Controls (n = 420) | 231 (55%) | 167 (39.8%) | 22 (5.2%) |  |
Positive Family History | Cancers (n = 193) | 129 (66.8%) | 55 (28.5%) | 9 (4.7%) | X2 = 8.75; p = 0.003* |
 | Controls (n = 91) | 43 (47.3%) | 41 (45.1%) | 7 (7.7%) |  |
Negative Family History | Cancers (n = 498) | 281 (56.4%) | 187 (37.6%) | 30 (6%) | X2 = 0.26; p = 0.61 |
 | Controls (n = 329) | 188 (57.1%) | 126 (38.3%) | 15 (4.6%) |  |
Young cancers vs. controls | Cancers (n = 112) | 64 (57.1%) | 41 (36.6%) | 7 (6.3%) | X2 = 0.03; p = 0.86 |
 | Controls (n = 420) | 231 (55%) | 167 (39.8%) | 22 (5.2%) |  |
IL1RN +2018 T>C | |||||
Overall | Cancers (n = 697) | 349 (50.1%) | 286 (41%) | 62 (8.9%) | X2 = 0.05; p = 0.82 |
 | Controls (n = 490) | 247 (50.4%) | 202 (41.2%) | 41 (8.4%) |  |
Positive Family History | Cancers (n = 193) | 94 (48.7%) | 84 (43.5%) | 15 (7.8%) | X2 = 0.074; p = 0.79 |
 | Controls (n = 103) | 48 (46.6%) | 47 (45.6%) | 8 (7.8%) |  |
Negative Family History | Cancers (n = 504) | 255 (50.6%) | 202 (40.1%) | 47 (9.3%) | X2 = 0.14; p = 0.71 |
 | Controls (n = 387) | 199 (51.4%) | 155 (40.1%) | 33 (8.5%) |  |
Young cancers vs. controls | Cancers (n = 113) | 61 (54%) | 44 (38.9%) | 8 (7.1%) | X2 = 0.53; p = 0.47 |
 | Controls (n = 490) | 247 (50.4%) | 202 (41.2%) | 41 (8.4%) |  |
IL4R +1902 A>G | |||||
Overall | Cancers (n = 775) | 493 (63.6%) | 249 (32.1%) | 33 (4.3%) | X2 = 2.1; p = 0.15 |
 | Controls (n = 767) | 451 (58.8%) | 288 (37.5%) | 28 (3.7%) |  |
Positive Family History | Cancers (n = 212) | 133 (62.7%) | 70 (33%) | 9 (4.2%) | X2 = 0.19; p = 0.66 |
 | Controls (n = 168) | 98 (58.3%) | 66 (39.3%) | 4 (2.4%) |  |
Negative Family History | Cancers (n = 563) | 360 (63.9%) | 179 (31.8%) | 24 (4.3%) | X2 = 2.00; p = 0.16 |
 | Controls (n = 599) | 353 (58.9%) | 222 (37.1%) | 24 (4.0%) |  |
Young cancers vs. controls | Cancers (n = 122) | 85 (69.7%) | 36 (29.5%) | 1 (0.8%) | X2 = 6.36; p = 0.012* |
 | Controls (n = 767) | 451 (58.8%) | 288 (37.5%) | 28 (3.7%) |  |
IL6 -174 G>C | |||||
Overall | Cancers (n = 497) | 170 (34.2%) | 244 (49.1%) | 83 (16.7%) | X2 = 0.05; p = 0.83 |
 | Controls (n = 490) | 168 (34.3%) | 235 (48%) | 87 (17.8%) |  |
Positive Family History | Cancers (n = 127) | 47 (37%) | 55 (43.3%) | 25(19.7%) | X2 = 0.20; p = 0.66 |
 | Controls (n = 102) | 38 (37.3%) | 48 (47.1%) | 16(15.7%) |  |
Negative Family History | Cancers (n = 370) | 123 (33.2%) | 189 (51.1%) | 58 (15.7%) | X2 = 1.22; p = 0.64 |
 | Controls (n = 388) | 130 (33.5%) | 187 (48.2%) | 71 (18.3%) |  |
Young cancers vs. controls | Cancers (n = 85) | 36 (42.4%) | 31 (36.5%) | 18 (21.2%) | X2 = 0.31; p = 0.58 |
 | Controls (n = 490) | 168 (34.3%) | 235 (48%) | 87 (17.8%) |  |
IL10 -1082 G>A | |||||
Overall | Cancers (n = 497) | 121 (24.3%) | 253 (50.9%) | 123 (24.7%) | X2 = 0.01; p = 0.93 |
 | Controls (n = 498) | 117 (23.5%) | 260 (52.2%) | 121 (24.3%) |  |
Positive Family History | Cancers (n = 126) | 31 (24.6%) | 69 (54.8%) | 26 (20.6%) | X2 = 0.39; p = 0.54 |
 | Controls (n = 104) | 31 (29.8%) | 52 (50%) | 21 (20.2%) |  |
Negative Family History | Cancers (n = 371) | 90 (24.3%) | 184 (49.6%) | 97 (26.1%) | X2 = 0.11; p = 0.74 |
 | Controls (n = 394) | 86 (21.8%) | 208 (52.8%) | 100 (25.4%) |  |
Young cancers vs. controls | Cancers (n = 84) | 17 (20.2%) | 44 (52.4%) | 23 (27.4%) | X2 = 0.60; p = 0.44 |
 | Controls (n = 498) | 117 (23.5%) | 260 (52.2%) | 121 (24.3%) |  |